A Review of Mixed‐Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis

Abstract

Population modeling of tumor size dynamics has recently emerged as an important tool in pharmacometric research. A series of new mixed‐effects models have been reported recently, and we present herein a synthetic view of models with published mathematical equations aimed at describing the dynamics of tumor size in cancer patients following anticancer drug treatment. This selection of models will constitute the basis for the Drug Disease Model Resources (DDMoRe) repository for models on oncology. CPT: Pharmacometrics & Systems Pharmacology (2014) 3, e113; doi: 10.1038/psp.2014.12 ; advance online publication 7 May 2014

Shown for reading. Its publisher allows quoting it, not republishing it.

References 70

1. 1.

   Rodriguez-Brenes I.A. Komarova N.L. Wodarz D. Tumor growth dynamics: insights into evolutionary processesTrends Ecol. Evol285976042013

   Not in our library10.1016/j.tree.2013.05.020

2. 2.

   Bernard A. Kimko H. Mital D. Poggesi I. Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug developmentExpert Opin. Drug Metab. Toxicol8105710692012

   Not in our library10.1517/17425255.2012.693480

3. 3.

   Bender B.C. Schindler E. Friberg L.E. Population pharmacokinetic pharmacodynamic modelling in oncology: a tool for predicting clinical responseBr. J. Clin. Pharmacole-pub ahead of print 18 October 2013 http://www.ncbi.nlm.nih.gov/pubmed/24134068.

   Not in our library10.1111/bcp.12258

4. 4.

   Bonate P. Modeling tumor growth in oncologyPharmacokinetics in Drug Developmenteds. Bonate, P.L. & Howard, D.R.) 119SpringerNew York2011

   Not in our library

5. 5.
   Dynamics of Tumor Growth · 1964

   No notice
6. 6.

   Mayneord W.V. On a law of growth of Jensen's rat sarcomaAm. J. Cancer168418461932

   Not in our library

7. 7.
   Deciphering death: a commentary on Gompertz (1825) ‘On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies’ · 2015

   No notice
8. 8.

   Sullivan P.W. Salmon S.E. Kinetics of tumor growth and regression in IgG multiple myelomaJ. Clin. Invest51169717081972

   Not in our library10.1172/jci106971

9. 9.

   Bloom H.J. Richardson W.W. Harries E.J. Natural history of untreated breast cancer (1805–1933). Comparison of untreated and treated cases according to histological grade of malignancyBMJ22132211962

   Not in our library10.1136/bmj.2.5299.213

10. 10.

    Norton L. A Gompertzian model of human breast cancer growthCancer Res48706770711988

    Not in our library

11. 11.

    Eisenhauer E.A. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur. J. Cancer452282472009

    Not in our library10.1016/j.ejca.2008.10.026

12. 12.

    Ratain M.J. Eckhardt S.G. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECISTJ. Clin. Oncol22444244452004

    Not in our library10.1200/jco.2004.07.960

13. 13.

    Sharma M.R. Maitland M.L. Ratain M.J. RECIST: no longer the sharpest tool in the oncology clinical trials toolbox—pointCancer Res72514551492012

    Not in our library10.1158/0008-5472.can-12-0058

14. 14.

    US Food and Drug Administration.Innovation or stagnation: challenge and opportunity on the critical path to new medical products. < < http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/ CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm113411.pdf > ( 2004

    Not in our library

15. 15.

    Bruno R. Claret L. On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studiesClin. Pharmacol. Ther861361382009

    Not in our library10.1038/clpt.2009.97

16. 16.

    Claret L. Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancerJ. Clin. Oncol31211021142013

    Not in our library10.1200/jco.2012.45.0973

17. 17.

    Tham L.S. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patientsClin. Cancer Res14421342182008

    Not in our library10.1158/1078-0432.ccr-07-4754

18. 18.

    Wang Y. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug developmentClin. Pharmacol. Ther861671742009

    Not in our library10.1038/clpt.2009.64

19. 19.

    Houk B.E. Bello C.L. Poland B. Rosen L.S. Demetri G.D. Motzer R.J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysisCancer Chemother. Pharmacol663573712010

    Not in our library10.1007/s00280-009-1170-y

20. 20.

    Stein A., Wang W. Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trialBMC Cancer123112012

    Not in our library10.1186/1471-2407-12-311

21. 21.

    Maitland M.L. Estimation of renal cell carcinoma treatment effects from disease progression modelingClin. Pharmacol. Ther933453512013

    Not in our library10.1038/clpt.2012.263

22. 22.

    Bonate P.L. Suttle A.B. Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinomaCancer Chemother. Pharmacol722312402013

    Not in our library10.1007/s00280-013-2191-0

23. 23.

    Claret L. Lu J.F. Sun Y.N. Bruno R. Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancerCancer Chemother. Pharmacol66114111492010

    Not in our library10.1007/s00280-010-1449-z

24. 24.

    Frances N. Claret L. Bruno R. Iliadis A. Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancerCancer Chemother. Pharmacol68141314192011

    Not in our library10.1007/s00280-011-1628-6

25. 25.

    Stein W.D., Gulley J.L. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacyClin. Cancer Res179079172011

    Not in our library10.1158/1078-0432.ccr-10-1762

26. 26.

    Hansson E.K. PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GISTCPT Pharmacometrics Syst. Pharmacol2e842013

    Not in our library10.1038/psp.2013.61

27. 27.

    Ribba B. A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapyClin. Cancer Res18507150802012

    Not in our library10.1158/1078-0432.ccr-12-0084

28. 28.

    Bonate P.L. Suttle B. Effect of censoring due to progressive disease on tumor size kinetic parameter estimatesAAPS J158328392013

    Not in our library10.1208/s12248-013-9487-1

29. 29.

    Claret L. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamicsJ. Clin. Oncol27410341082009

    Not in our library10.1200/jco.2008.21.0807

30. 30.

    Wharton S.B. Chan K.K. Anderson J.R. Stoeber K. Williams G.H. Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosisNeuropathol. Appl. Neurobiol273053132001

    Not in our library10.1046/j.0305-1846.2001.00333.x

31. 31.

    Hahnfeldt P. Panigrahy D. Folkman J. Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancyCancer Res59477047751999

    Not in our library

32. 32.

    Rocchetti M. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenograftsCancer Chemother. Pharmacol71114711572013

    Not in our library10.1007/s00280-013-2107-z

33. 33.

    Ribba B. A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkersEur. J. Cancer474794902011

    Not in our library10.1016/j.ejca.2010.10.003

34. 34.

    Mandonnet E. Continuous growth of mean tumor diameter in a subset of grade II gliomasAnn. Neurol535245282003

    Not in our library10.1002/ana.10528

35. 35.

    Beal S. NONMEM User's GuidesI.D. SolutionsEllicott City, Maryland1989–2009

    Not in our library

36. 36.

    Hansson E.K. PKPD modeling of predictors for adverse effects and overall survival in sunitinib-treated patients with GISTCPT Pharmacometrics Syst. Pharmacol2e852013

    Not in our library10.1038/psp.2013.62

37. 37.

    Simeoni M. De Nicolao G. Magni P. Rocchetti M. Poggesi I. Modeling of human tumor xenografts and dose rationale in oncologyDrug Discov. Today Technol10e365e3722013

    Not in our library10.1016/j.ddtec.2012.07.004

38. 38.

    Lobo E.D. Balthasar J.P. Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitroAAPS PharmSci4E422002

    Not in our library10.1208/ps040442

39. 39.

    Mager D.E. Jusko W.J. Pharmacodynamic modeling of time-dependent transduction systemsClin. Pharmacol. Ther702102162001

    Not in our library10.1067/mcp.2001.118244

40. 40.

    Simeoni M. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agentsCancer Res64109411012004

    Not in our library10.1158/0008-5472.can-03-2524

41. 41.

    Shah D.K. Haddish-Berhane N. Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotinJ. Pharmacokinet. Pharmacodyn396436592012

    Not in our library10.1007/s10928-012-9276-y

42. 42.

    Haddish-Berhane N. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approachJ. Pharmacokinet. Pharmacodyn405575712013

    Not in our library10.1007/s10928-013-9329-x

43. 43.

    Bueno L. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in miceEur. J. Cancer441421502008

    Not in our library10.1016/j.ejca.2007.10.008

44. 44.

    Friberg L.E. Henningsson A. Maas H. Nguyen L. Karlsson M.O. Model of chemotherapy-induced myelosuppression with parameter consistency across drugsJ. Clin. Oncol20471347212002

    Not in our library10.1200/jco.2002.02.140

45. 45.

    Hart D. Shochat E. Agur Z. The growth law of primary breast cancer as inferred from mammography screening trials dataBr. J. Cancer783823871998

    Not in our library10.1038/bjc.1998.503

46. 46.

    Kola I. Landis J. Can the pharmaceutical industry reduce attrition ratesNat. Rev. Drug Discov37117152004

    Not in our library10.1038/nrd1470

47. 47.

    Girard P. Tumor size model and survival analysis of cetuximab and various cytotoxics in patients treated for metastatic colorectal cancer. < < http://www.page-meeting.org/?abstract=2902%5D > ( 2013

    Not in our library

48. 48.

    Vainas O. Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational modelBr. J. Cancer1078148222012

    Not in our library10.1038/bjc.2012.316

49. 49.

    Kogan Y. Halevi-Tobias K. Elishmereni M. Vuk-Pavlović S. Agur Z. Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalizationCancer Res72221822272012

    Not in our library10.1158/0008-5472.can-11-4166

50. 50.

    Gorelik B. Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical modelCancer Res68903390402008

    Not in our library10.1158/0008-5472.can-08-1723

51. 51.

    Parra-Guillen Z.P. Berraondo P. Grenier E. Ribba B. Troconiz I.F. Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategiesAAPS J157978072013

    Not in our library10.1208/s12248-013-9483-5

52. 52.

    Parra-Guillen Z.P. Berraondo P. Ribba B. Trocóniz I.F. Modeling tumor response after combined administration of different immune-stimulatory agentsJ. Pharmacol. Exp. Ther3464324422013

    Not in our library10.1124/jpet.113.206961

53. 53.

    Elishmereni M. Kheifetz Y. Søndergaard H. Overgaard R.V. Agur Z. An integrated disease/pharmacokinetic/pharmacodynamic model suggests improved interleukin-21 regimens validated prospectively for mouse solid cancersPLoS Comput. Biol7e10022062011

    Not in our library10.1371/journal.pcbi.1002206

54. 54.

    Jager E. van der Velden V.H. te Marvelde J.G. Walter R.B. Agur Z. Vainstein V. Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualizationPLoS One6e242652011

    Not in our library10.1371/journal.pone.0024265

55. 55.

    Terranova N. Germani M. Del Bene F. Magni P. A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combinationCancer Chemother. Pharmacol724714822013

    Not in our library10.1007/s00280-013-2208-8

56. 56.

    Krippendorff B.F. Kuester K. Kloft C. Huisinga W. Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosisJ. Pharmacokinet. Pharmacodyn362392602009

    Not in our library10.1007/s10928-009-9120-1

57. 57.

    Wong H. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical responseClin. Cancer Res18384638552012

    Not in our library10.1158/1078-0432.ccr-12-0738

58. 58.

    Rocchetti M. Simeoni M. Pesenti E. De Nicolao G. Poggesi I. Predicting the active doses in humans from animal studies: a novel approach in oncologyEur. J. Cancer43186218682007

    Not in our library10.1016/j.ejca.2007.05.011

59. 59.

    Keizer R.J. Schellens J.H. Beijnen J.H. Huitema A.D. Pharmacodynamic biomarkers in model-based drug development in oncologyCurr. Clin. Pharmacol630402011

    Not in our library10.2174/157488411794941368

60. 60.

    Almufti R. A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatmentAnn. Oncol2541562014

    Not in our library10.1093/annonc/mdt382

61. 61.

    Kronik N. Kogan Y. Elishmereni M. Halevi-Tobias K. Vuk-Pavlović S. Agur Z. Predicting outcomes of prostate cancer immunotherapy by personalized mathematical modelsPLoS One5e154822010

    Not in our library10.1371/journal.pone.0015482

62. 62.

    Komarova N.L. Wodarz D. Effect of cellular quiescence on the success of targeted CML therapyPLoS One2e9902007

    Not in our library10.1371/journal.pone.0000990

63. 63.

    Kronik N. Kogan Y. Vainstein V. Agur Z. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamicsCancer Immunol. Immunother574254392008

    Not in our library10.1007/s00262-007-0387-z

64. 64.
    Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy · 2002

    No notice
65. 65.

    Swanson K.R. Bridge C. Murray J.D. Alvord E.C. Jr Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasionJ. Neurol. Sci2161102003

    Not in our library10.1016/j.jns.2003.06.001

66. 66.

    Harpold H.L. Alvord E.C. Jr Swanson K.R. The evolution of mathematical modeling of glioma proliferation and invasionJ. Neuropathol. Exp. Neurol66192007

    Not in our library10.1097/nen.0b013e31802d9000

67. 67.

    Ribba B. Colin T. Schnell S. A multiscale mathematical model of cancer, and its use in analyzing irradiation therapiesTheor. Biol. Med. Model.372006

    Not in our library10.1186/1742-4682-3-7

68. 68.

    Lignet F. Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted miceJ. Theor. Biol32086992013

    Not in our library10.1016/j.jtbi.2012.12.013

69. 69.

    Vigneaux P. Louvet V. Grenier E. Extending Monolix to use models with partial differential equations. < < http://www.page-meeting.org/?abstract=2666%5D > ( 2013

    Not in our library

70. 70.

    Barthelemy C. Lavielle M. New methods for complex models defined by a large number of ODEs. Application to a glucose/insulin model. < < http://www.page-meeting.org/?abstract=2852%5D > ( 2013

    Not in our library

Cited by papers we hold 2

• Therapeutic drug monitoring of oral targeted antineoplastic drugs · 2020
  Corrected
• Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth · 2014
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.